Web Exclusives

Why current immigration plans are not adequette to deal with the growing crisis

Mental health is in the public eye like never before, but research and funding is still behind other areas

An interview with Professor Sylvia Haas on how best to prevent stroke in patients with atrial fibrillation and co-morbidities

EMIG’s Leslie Galloway on how the government’s recent actions could destroy pharma in the UK

The push for greater transparency across the industry brings new opportunities for companies to innovate

Recent rulings on supplementary protection certificates may raise more questions than answers

How a holistic approach requires a paradigm shift from pharma sales

When faced with a dizzying array of CROs of different profiles, sizes and locations, how do sponsors know who to trust?

How an intelligent pharmaceutical supply chain enhances patient-caregiver experience

The need to challenge conventions

There is still much to do to realise the full cost saving benefits of biosimilars, and much of this boils down to clinical confidence

A growing body of evidence suggests that two-drug regimens could be hugely important for HIV patients

Patient-centricity, biotech and new data tech have all characterised a record H1 for pharma deals

CRISPR could help turn Alzhimer’s findings into a cure, but there are several barriers to overcome first

An overview of the latest drug developments in this notoriously-difficult disease area